Antibodies

11 Apr 2019 Intas Pharmaceuticals Launches its Trastuzumab Biosimilar, Eleftha® - Further Bringing Down the Treatment Cost by 65%
10 Apr 2019 Sound Biologics Announces FDA Allowance of its IND Application for PSB205, an Anti-PD-1/CTLA-4 MabPair, in Relapsed and Refractory Solid Tumors
10 Apr 2019 FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
09 Apr 2019 Provention Bio Initiates Phase 3 PROTECT Clinical Trial with PRV-031 (Teplizumab) in Patients with Recent Onset Type 1 Diabetes
09 Apr 2019 Generium Launches First Biosimilar of Eculizumab; Becomes Fifth Marketed Product Using Selexis SUREtechnology Platform
06 Apr 2019 Acceleron Discontinues Development of Phase 1 Molecule ACE-2494
05 Apr 2019 Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA
05 Apr 2019 Merrimack Discontinues Development of MM-310
05 Apr 2019 Fresenius Kabi Receives European Commission Approval For Adalimumab Biosimilar IDACIO
04 Apr 2019 Further record year of biologics sales in 2018 due to innovative antibodies
03 Apr 2019 AACR 2019 Presentations Highlight CX-2009, a First-In-Class Probody Drug Conjugate Targeting Novel Tumor Antigen, CD166
03 Apr 2019 Aptevo Therapeutics Presents New Preclinical Data for APVO436 and ALG.APV-527 at the American Association for Cancer Research 2019 Annual Meeting
03 Apr 2019 Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the 2019 American Association for Cancer Research (AACR) Annual Meeting
03 Apr 2019 Agenus Begins Dosing with Next-Gen Anti-CTLA-4 Antibody
03 Apr 2019 Rgenix Presents Pre-Clinical Data on RGX-019 at the 2019 AACR Annual Meeting
03 Apr 2019 Alligator Bioscience: New preclinical data for ATOR-1144 demonstrate potential for activation of both the innate and the adaptive immune system, as well as direct anti-tumor effects
03 Apr 2019 Pieris Pharmaceuticals Presents Preclinical Data for GPC3/4-1BB Bispecific PRS-342 at the 2019 American Association for Cancer Research
02 Apr 2019 Celldex Presents Positive Interim Results from Phase 1 Study of CD40 Agonist CDX-1140 at American Association for Cancer Research (AACR) Annual Meeting 2019
02 Apr 2019 Apexigen Presents Clinical Data On CD40 Antibody APX005M In Metastatic Melanoma At The AACR Annual Meeting 2019
02 Apr 2019 Nordic Nanovector: Promising Results From Preclinical Studies With a Novel CD37-targeted Alpha Therapy for B-cell Tumours Presented at TAT11
02 Apr 2019 Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019
02 Apr 2019 Affimed Highlights AFM24 Innate Cell Engager Novel Mechanism of Action and Potential for the Treatment of EGFR-expressing Solid Tumors at the American Association for Cancer Research (AACR) 2019 Annual Meeting
02 Apr 2019 Outlook Therapeutics Announces FDA Acceptance of IND for ONS-5010
02 Apr 2019 Triphase Accelerator Initiates Phase 1 Clinical Trial of TRPH-222 in B-cell Lymphoma
02 Apr 2019 Humanigen Announces Preliminary Results From Ifabotuzumab Phase I Study Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top